<DOC>
	<DOCNO>NCT01184092</DOCNO>
	<brief_summary>In study , 10 mg dose tasocitinib ( CP-690,550 ) give study subject three separate occasion use one three different tablet formulation ( tablet version ) time . The amount tasocitinib ( CP-690,550 ) available blood follow administration tablet formulation measure compare . The overall aim study establish similar amount tasocitinib ( CP-690,550 ) absorb blood follow administration dose different tablet formulation .</brief_summary>
	<brief_title>A Study To Compare The Amount Of Tasocitinib ( CP-690,550 ) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib ( CP-690,550 )</brief_title>
	<detailed_description>This pivotal bioequivalence study tasocitinib ( CP-690,550 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female ( nonchildbearing potential ) subject age 21 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight male &gt; 50 kg ( 110 lb ) . For female , total body weight &gt; 45 kg ( 99 lb ) . No evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) . Evidence clinically significant illness , medical condition , disease . Evidence history clinically significant infection within past 3 month . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>healthy volunteer study</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>